Chris Schott

In a report published Monday, J.P. Morgan analyst Chris Schott reiterated an Overweight rating and $39.00 price target on Zoetis (NYSE: ZTS). In the report, J.P. Morgan noted, “Following the Pfizer share exchange making Zoetis a fully publicly-owned company, we wanted to revisit our thesis on...

In a report published on Wednesday analysts from JP Morgan raised its price target on Mylan (NASDAQ: MYL) from $34 to $38 and maintained an Overweight rating on the company. In the report lead analyst Chris Schott commented that, "Consolidation has been the core theme within the specialty/...

Warner Chilcott (NASDAQ: WCRX) will likely be added to the Russell 1000 on Friday, June 11 and should serve as an NT catalyst for the shares. An inclusion in the S&P 500 later this year is also possible. JP Morgan analysts Chris Schott, Dewey Steadman, and Jessica Fye rate WCRX Overweight. The...

Shares of Forest Laboratories Inc. (NYSE: FRX) closed Tuesday trading up 5.65% at $27.67 per share. Forest Laboratories Inc. opened Tuesday morning at $27.87 per share, and didn't show many dramatic movements for the rest of the day, trading between $27.22 and $28.14 per share. Volume of nearly 15...

J.P. Morgan analysts Chris Schott, Dewey Steadman and Jessica Fye maintained their rating of Underweight for shares of Forest Laboratories, Inc. (NYSE: FRX), with a price target of $27 per share. The analysts said that it's unlikely that Daxas will prove to be a meaningful earnings driver for...